RT Book, Section A1 Dixon, Dave L. A1 Riche, Daniel M. A1 Kelly, Michael S. A2 DiPiro, Joseph T. A2 Yee, Gary C. A2 Haines, Stuart T. A2 Nolin, Thomas D. A2 Ellingrod, Vicki L. A2 Posey, L. Michael SR Print(0) ID 1205561521 T1 Dyslipidemia T2 DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, 12th Edition YR 2023 FD 2023 PB McGraw Hill PP New York, NY SN 9781264264544 LK accesspharmacy.mhmedical.com/content.aspx?aid=1205561521 RD 2024/11/14 AB Update SummaryJuly, 2023The following sections, tables, and figures were updated:The chapter has been revised in several sections to reflect the results of the CLEAR-OUTCOMES study, which provides evidence regarding the potential role of bempedoic acid in the prevention of cardiovascular events. Revisions include updates to the following sections:General Approach to TreatmentTable 32-3 Select Landmark Clinical TrialsAdenosine Triphosphate-Citrate Lyase InhibitorsA new paragraph was added to the “Dietary Supplements” section reflecting the results of the SPORT trial which compared rosuvastatin to six commonly used dietary supplements.Updates were made throughout the chapter to change PCSK9 inhibitors to the preferred terminology PCSK9 monoclonal antibody (PCSK9 mAb), including Figure 32-7.Revisions are done to Figure 32-8 clarifying the approach to treatment of hypertriglyceridemia.Information is added about the nocebo effect and how to mitigate it in the “HMG-CoA Reductase Inhibitors” (Statins) section.The REPRIEVE study provides new evidence regarding the benefits of statin therapy in patients with human immunodeficiency virus (HIV) infection; updates were made to the “Patients with Chronic Inflammatory Disorders and HIV” section.